trending Market Intelligence /marketintelligence/en/news-insights/trending/d9J6uYnQKRSHEDBXGZlqPQ2 content esgSubNav
In This List

Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Thermo Fisher Scientific Inc. and Juno Therapeutics Inc. entered into a partnership for Juno to use Thermo Fisher's Cell Therapy Systems activation reagents in the manufacturing of its chimeric antigen receptor T cell, or CAR-T cell, therapies.

Under the seven-year nonexclusive licensing and supply agreement, Thermo Fisher granted Juno rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for Juno's current and future CAR-T cell therapies, which work by manipulating a patient's own disease-fighting T-cells and then infusing them back into the body to fight blood cancers.

CTS Dynabeads activate and expand T-cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.

The companies did not disclose the financial details of the transaction.